Barclays PLC Acquires 154,436 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Barclays PLC lifted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 391.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 193,873 shares of the biopharmaceutical company’s stock after purchasing an additional 154,436 shares during the period. Barclays PLC owned 0.08% of Lexicon Pharmaceuticals worth $304,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in LXRX. Bank of New York Mellon Corp increased its stake in shares of Lexicon Pharmaceuticals by 37.6% in the second quarter. Bank of New York Mellon Corp now owns 401,908 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 109,902 shares during the period. Principal Financial Group Inc. grew its position in Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares in the last quarter. Rhumbline Advisers grew its position in Lexicon Pharmaceuticals by 13.3% during the second quarter. Rhumbline Advisers now owns 152,785 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 17,940 shares in the last quarter. Victory Capital Management Inc. grew its position in Lexicon Pharmaceuticals by 44.5% during the second quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 13,972 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Lexicon Pharmaceuticals by 52.3% during the second quarter. Dimensional Fund Advisors LP now owns 76,086 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 26,143 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Stock Up 1.5 %

NASDAQ LXRX opened at $0.79 on Monday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. The stock’s 50 day moving average is $0.96 and its two-hundred day moving average is $1.49. The company has a market capitalization of $194.18 million, a price-to-earnings ratio of -1.05 and a beta of 1.06. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.62 and a 1-year high of $3.73.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. During the same period in the previous year, the firm posted ($0.21) earnings per share. Equities analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.00.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.